Sruthi Arepalli, MD, an assistant professor at Emory Eye Center in Atlanta, Georgia, presented a comprehensive study on secondary lens implants in patients with uveitis at the 2025 ASRS meeting.

Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025.

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

Lai spoke with Modern Retina about the study of PER-001, a novel therapeutic targeting the endothelin-1 receptor. Michael Lai, MD, PhD, presented at the 2025 annual scientific meeting of the American ...

Panelists discuss how their management approach for geographic atrophy (GA) has evolved from a “come back in a year” mentality to actively offering treatment discussions within 2 to 3 months, with ...

EP: 4. Choosing Between the Currently Available GA Therapies Therapy selection between the 2 FDA-approved geographic atrophy treatments presents a complex clinical decision without clear superiority ...

At the 2025 annual scientific meeting of the American Society of Retina Specialists (ASRS), Jay Chhablani, MD, Vice Chair at University of Pittsburgh Medical Center gave a presentation titled, "Safety ...

Retina Group of WashingtonLai spoke with Modern Retina about the study of PER-001, a novel therapeutic targeting the endothelin-1 receptor.

Steven D. Ness, MD, an attending physician at the VA Boston Healthcare System and assistant professor at Boston University, presented a study examining the relationship between vitamin D levels and ...

Avant Technologies and Ainnova Tech refine clinical trial protocol for Vision AI platform, aiming for FDA 510(k) approval to enhance diabetic retinopathy detection.

Nimesh A. Patel, MD, FASRS, from Mass Eye and Ear Hospital and Boston Children's Hospital presented a real-world study using the Vestrum database to examine usage trends for pegcetacoplan and ...

Newsletter Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.